Author Correction: Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination

Author Correction: Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination

Saved in:

Bibliographic Details
Main Authors:	Jing-Xing Li, Yu-Hsun Wang, Henry Bair, Shu-Bai Hsu, Connie Chen, James Cheng-Chung Wei, Chun-Ju Lin
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-11-01
Series:	npj Vaccines
Online Access:	https://doi.org/10.1038/s41541-024-01026-4
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination
by: Jing-Xing Li, et al.
Published: (2024-10-01)

Authors' Reply
by: Natasha F S Cruz, et al.
Published: (2022-11-01)

Author’s Reply
by: Ishan Kumar, et al.
Published: (2025-01-01)

Author's Reply
by: Giovanni de Gaetano
Published: (2024-12-01)

Authors’ Reply
by: Meghana Bhupathi, et al.
Published: (2024-12-01)

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination
by: Brian Shine, et al.
Published: (2024-04-01)

mRNA vaccines as cancer therapies
by: Shaoxiong Huang, et al.
Published: (2024-12-01)

Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
by: Ramandip Grewal, et al.
Published: (2024-12-01)

mRNA vaccine politics: responsible governance coordination for vaccine innovation in times of urgency
by: Katerina Sideri
Published: (2024-12-01)

Authors' Reply to Torpedo Retinopathy or Chorioretinopathy?
by: Ramesh Venkatesh, et al.
Published: (2022-11-01)

Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques
by: Lulu Huang, et al.
Published: (2024-12-01)

Real world experience of brolucizumab in recalcitrant macular edema in retinal vein occlusions (RVO’s): 12 months follow up – A pilot study
by: Shilpi H Narnaware, et al.
Published: (2024-12-01)

mRNA Vaccines Against Infectious Diseases and Cancer
by: Alexander Meisel, et al.
Published: (2021-10-01)

mRNA vaccine designs for optimal adjuvanticity and delivery
by: Yuki Mochida, et al.
Published: (2024-12-01)

Research progress on the quality control of mRNA vaccines
by: Chaoying Hu, et al.
Published: (2024-12-01)

Authors’ Reply: Reassessing AI in Medicine: Exploring the Capabilities of AI in Academic Abstract Synthesis
by: Tien-Wei Hsu, et al.
Published: (2024-12-01)

Authors' Reply to Comments from Dr. Guan
by: Ken-ichiro Inoue, et al.
Published: (2009-01-01)

Reply to “Vaccination caused underestimation of cumulative incidence of SARS-CoV-2 infection”
by: Jefferson M. Jones, et al.
Published: (2025-02-01)

Research progress of mosquito-borne virus mRNA vaccines
by: Ningze Sun, et al.
Published: (2025-03-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01)

Editorial: Building public confidence in innovative mRNA vaccines
by: Jia Hu, et al.
Published: (2025-01-01)

Mapping global public perspectives on mRNA vaccines and therapeutics
by: Jiaxiang Xu, et al.
Published: (2024-11-01)

Bacteriophage RNA polymerases: catalysts for mRNA vaccines and therapeutics
by: Adithya Nair, et al.
Published: (2024-11-01)

Author Correction: Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine
by: Anannya Bhattacharya, et al.
Published: (2024-11-01)

Influenza Vaccination Rates, Perceptions, and Vaccine Hesitancy in K-12 Teachers and Staff
by: Kevin Cleveland, et al.
Published: (2025-02-01)

Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea
by: Mijeong Ko, et al.
Published: (2024-08-01)

mRNA vaccines in the context of cancer treatment: from concept to application
by: Qiang Fu, et al.
Published: (2025-01-01)

The Immunologic Downsides Associated with the Powerful Translation of Current COVID-19 Vaccine mRNA Can Be Overcome by Mucosal Vaccines
by: Maurizio Federico
Published: (2024-11-01)

Bioinformatics designing of an mRNA vaccine for Mokola virus (MOKV) using immunoinformatics as a secure strategy for successful vaccine development
by: Elijah Kolawole Oladipo, et al.
Published: (2024-11-01)

Authors’ Reply: Japan's Telepsychiatry Dissemination: Current Status and Challenges
by: Yuka Sugawara, et al.
Published: (2025-01-01)

Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine
by: Dandan Peng, et al.
Published: (2023-04-01)

Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza
by: Ziqi Cheng, et al.
Published: (2024-12-01)

Toxic Epidermal Necrolysis after COVID-19 mRNA-1237 Vaccination
by: Nicole Hehr, et al.
Published: (2023-01-01)

Myocarditis following mRNA COVID‐19 vaccination: call for endomyocardial biopsy
by: Daniel Kiblboeck, et al.
Published: (2022-06-01)

Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy
by: Saber Imani, et al.
Published: (2025-01-01)

Myocarditis Related-COVID-19 mRNA Vaccination: A Narrative Review
by: Idman Gushaendri, et al.
Published: (2023-06-01)

IL-7 promotes mRNA vaccine-induced long-term immunity
by: Lingli Wang, et al.
Published: (2024-11-01)

Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond
by: Elizabeth Adrianne Hammershaimb, et al.
Published: (2024-12-01)

Evolution of Workload Associated with Anti-VEGF Treatments for AMD, DME, RVO and mCNV in Hospital District of Southwest Finland
by: Heloterä H, et al.
Published: (2024-12-01)

Authors’ Reply: Advancing Insights Into Postoperative Sleep Quality and Influencing Factors
by: Chen Shang, et al.
Published: (2025-02-01)